アレルギー性喘息(Allergic Asthma):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Allergic Asthma - Pipeline Review, H2 2014
◆商品コード:GMDHC5790IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:145
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるアレルギー性喘息(Allergic Asthma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・アレルギー性喘息(Allergic Asthma)の概要
・アレルギー性喘息(Allergic Asthma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・アレルギー性喘息(Allergic Asthma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・アレルギー性喘息(Allergic Asthma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・アレルギー性喘息(Allergic Asthma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Allergic Asthma – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Allergic Asthma – Pipeline Review, H2 2014’, provides an overview of the Allergic Asthma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Allergic Asthma Overview 10
Therapeutics Development 11
Pipeline Products for Allergic Asthma – Overview 11
Pipeline Products for Allergic Asthma – Comparative Analysis 12
Allergic Asthma – Therapeutics under Development by Companies 13
Allergic Asthma – Therapeutics under Investigation by Universities/Institutes 16
Allergic Asthma – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Allergic Asthma – Products under Development by Companies 20
Allergic Asthma – Products under Investigation by Universities/Institutes 22
Allergic Asthma – Companies Involved in Therapeutics Development 23
AIM Therapeutics Inc. 23
ALK-Abello A/S 24
Allergopharma Joachim Ganzer KG 25
Array BioPharma Inc. 26
Aslan Pharmaceuticals Pte. Ltd. 27
Asmacure Ltee 28
BioTech Tools s.a. 29
Fountain Biopharma Inc. 30
Genentech, Inc. 31
Infinity Pharmaceuticals, Inc. 32
Kineta, Inc. 33
Marinomed Biotechnologie GmbH 34
NeoPharm Co., Ltd. 35
Novartis AG 36
Nuvo Research Inc. 37
Panacea Biotec Limited 38
Peptinnovate Limited 39
Pharmaxis Limited 40
Portola Pharmaceuticals, Inc. 41
Protectimmun GmbH 42
Pulmatrix, Inc. 43
Stallergenes S.A. 44
sterna biologicals Gmbh & Co KG 45
Verona Pharma Plc 46
Allergic Asthma – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(fluticasone propionate + salmeterol xinafoate) – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Acaroid – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Actair – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AcTMP-1 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AIM-102 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
allergenic pollen extract of timothy – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Arabinogalactan – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ARRY-502 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ASLAN-004 – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ASM-024 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ASM-8 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
dalazatide – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Drug to Inhibit PI3 Kinase Delta for Asthma – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
duvelisib – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
E-3.56 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
FB-825 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
fevipiprant – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
hdm-ASIT – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Lactococcus lactis G121 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MAM-06301 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
MK-8237 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
omalizumab biosimilar – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
omalizumab biosimilar – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PIN-201601 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
PRT-2607 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
QGE-031 – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
quilizumab – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RPL-554 – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SB-010 – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SG-100 – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecule for Allergic Asthma – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecule for Allergic Asthma – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules for Allergic Asthma – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecules to Inhibit C-Rel for Central Nervous System, Immunology, Musculoskeletal, Oncology, Respiratory and Metabolic Disorders – Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Small Molecules to Inhibit CaMKII for Allergic Asthma – Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Timothy Grass Pollen Allergen Extract – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Vaccine for Allergic Rhinitis and Allergic Asthama – Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
WF-10 – Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
WF-10 liposomal – Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Allergic Asthma – Recent Pipeline Updates 111
Allergic Asthma – Dormant Projects 134
Allergic Asthma – Discontinued Products 137
Allergic Asthma – Product Development Milestones 138
Featured News & Press Releases 138
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 138
May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 139
May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 140
Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 140
Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 141
Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 142
Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 142
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 145
Disclaimer 145

[List of Tables]
Number of Products under Development for Allergic Asthma, H2 2014 11
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2014 22
Allergic Asthma - Pipeline by AIM Therapeutics Inc., H2 2014 23
Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2014 24
Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 25
Allergic Asthma - Pipeline by Array BioPharma Inc., H2 2014 26
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 27
Allergic Asthma - Pipeline by Asmacure Ltee, H2 2014 28
Allergic Asthma - Pipeline by BioTech Tools s.a., H2 2014 29
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2014 30
Allergic Asthma - Pipeline by Genentech, Inc., H2 2014 31
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 32
Allergic Asthma - Pipeline by Kineta, Inc., H2 2014 33
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2014 34
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2014 35
Allergic Asthma - Pipeline by Novartis AG, H2 2014 36
Allergic Asthma - Pipeline by Nuvo Research Inc., H2 2014 37
Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2014 38
Allergic Asthma - Pipeline by Peptinnovate Limited, H2 2014 39
Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2014 40
Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 41
Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2014 42
Allergic Asthma - Pipeline by Pulmatrix, Inc., H2 2014 43
Allergic Asthma - Pipeline by Stallergenes S.A., H2 2014 44
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 45
Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2014 46
Assessment by Monotherapy Products, H2 2014 47
Assessment by Combination Products, H2 2014 48
Number of Products by Stage and Target, H2 2014 50
Number of Products by Stage and Mechanism of Action, H2 2014 52
Number of Products by Stage and Route of Administration, H2 2014 54
Number of Products by Stage and Molecule Type, H2 2014 56
Allergic Asthma Therapeutics - Recent Pipeline Updates, H2 2014 111
Allergic Asthma - Dormant Projects, H2 2014 134
Allergic Asthma - Dormant Projects (Contd..1), H2 2014 135
Allergic Asthma - Dormant Projects (Contd..2), H2 2014 136
Allergic Asthma - Discontinued Products, H2 2014 137

[List of Figures]
Number of Products under Development for Allergic Asthma, H2 2014 11
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Products, H2 2014 19
Assessment by Monotherapy Products, H2 2014 47
Number of Products by Top 10 Targets, H2 2014 49
Number of Products by Stage and Top 10 Targets, H2 2014 49
Number of Products by Top 10 Mechanism of Actions, H2 2014 51
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 51
Number of Products by Top 10 Routes of Administration, H2 2014 53
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 54
Number of Products by Top 10 Molecule Types, H2 2014 55
Number of Products by Stage and Top 10 Molecule Types, H2 2014 56

【掲載企業】

AIM Therapeutics Inc.
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
Asmacure Ltee
BioTech Tools s.a.
Fountain Biopharma Inc.
Genentech, Inc.
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Marinomed Biotechnologie GmbH
NeoPharm Co., Ltd.
Novartis AG
Nuvo Research Inc.
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Portola Pharmaceuticals, Inc.
Protectimmun GmbH
Pulmatrix, Inc.
Stallergenes S.A.
sterna biologicals Gmbh & Co KG
Verona Pharma Plc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アレルギー性喘息(Allergic Asthma):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆